Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Archives of Virology
Published in: Archives of Virology 11/2016

01-11-2016 | Original Article

The inhibitory effect of dehydroepiandrosterone and its derivatives against influenza A virus in vitro and in vivo

Authors: Qingyu Yang, Qing Mao, Manli Liu, Kaimei Wang, Zhaoyuan Wu, Wei Fang, Ziwen Yang, Pengchen Luo, Shaoyong Ke, Liqiao Shi

Published in: Archives of Virology | Issue 11/2016

Login to get access

Abstract

The antiviral activity of dehydroepiandrosterone (DHEA) and 21 synthetic derivatives against influenza A virus (IAV) replication was investigated in vitro in cell culture. Our results revealed that three DHEA analogues were potent inhibitors of IAV multiplication in MDCK cells and mainly blocked the post-attachment stage of viral infection. Among these derivatives, one containing a 2-OH-Ph moiety (3i) exhibited the best inhibitory effects against H1N1 and H3N2 IAV in a dose-dependent manner. Moreover, treatment with compound 3i decreased progeny virus yields, viral RNA synthesis and protein expression. Orally administered compound 3i at 25 or 50 mg/kg/day for 5 days protected mice from lethal A/FM/1/47 (H1N1) challenge by reducing the viral titers in the lungs and promoting survival of infected mice. Our results suggest that DHEA-dihydrazone derivatives may provide promising lead scaffolds for further design and synthesis of potential antiviral agents.
Literature
1.
Nickel KB, Marsden-Haug N, Lofy KH, Turnberg WL, Rietberg K, Lloyd JK, Marfin AA (2011) Age as an independent risk factor for intensive care unit admission or death due to 2009 pandemic influenza A (H1N1) virus infection. Public Health Rep 126:349–353PubMedPubMedCentral
2.
3.
4.
5.
6.
Tsiodras S, Nikolopoulos G, Bonovas S (2012) Antivirals used for influenza chemoprophylaxis. Curr Med Chem 19:5947–5956CrossRefPubMed
7.
Hurt AC, Ho HT, Barr I (2006) Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors. Expert Rev Anti Infect Ther 4:795–805CrossRefPubMed
8.
McKimm-Breschkin JL (2013) Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance. Influenza Other Respir Viruses 1:25–36CrossRef
9.
Samaras N, Samaras D, Frangos E, Forster A, Philippe J (2013) A review of age-related dehydroepiandrosterone decline and its association with well-know geriatric syndromes: is treatment beneficial. Rejuvenation Res 16:285–294CrossRefPubMedPubMedCentral
10.
Brazão V, Santello FH, Caetano LC, Del Vecchio Filipin M, Toldo MP, do Prado JC Jr (2010) Immunomodulatory effects of zinc and DHEA on the Th-1 immune response in rats infected with Trypanosoma cruzi. Immunobiology 215:427–434CrossRefPubMed
11.
Lichte P, Pfeifer R, Werner BE, Ewers P, Tohidnezhad M, Pufe T, Hildebrand F, Pape HC, Kobbe P (2014) Dehydroepiandrosterone modulates the inflammatory response in a bilateral femoral shaft fracture model. Eur J Med Res 19:27–32CrossRefPubMedPubMedCentral
12.
Ke S, Wei Y, Shi L, Yang Q, Yang Z (2013) Synthesis of novel steroid derivatives derived from dehydroepiandrosterone as potential anticancer agents. Anticancer Agents Med Chem 13:1291–1298CrossRefPubMed
13.
Torres NI, Castilla V, Bruttomesso AC, Eiras J, Galagovsky LR, Wachsman MB (2012) In vitro antiviral activity of dehydroepiandrosterone, 17 synthetic analogs and ERK modulators against herpes simplex virus type 1. Antiviral Res 95:37–48CrossRefPubMed
14.
Henderson E, Schwartz A, Pashko L, Abou-Gharbia M, Swern D (1981) Dehydroepiandrosterone and 16 alpha-bromo-epiandrosterone: inhibitors of Epstein-Barr virus-induced transformation of human lymphocytes. Carcinogenesis 2:683–686CrossRefPubMed
15.
Loria RM, Inge TH, Cook SS, Szakal AK, Regelson W (1988) Protection against acute lethal vial infections with the native steroid dehydroepiandrosterone (DHEA). J Med Virol 26:301–314CrossRefPubMed
16.
Diallo K, Loemba H, Oliveira M, Mavoungou DD, Wainberg MA (2000) Inhibition of human immunodeficiency virus type-1 (HIV-1) replication by immunor (IM28), a new analog of dehydroepiandrosterone. Nucleosides Nucleotides Nucleic Acids 19:2019–2024CrossRefPubMed
17.
Padgett DA, MacCallum RC, Loria RM, Sheridan JF (2000) Androstenediol-induced restoration of responsiveness to influenza vaccination in mice. J Gerontol A Biol Sci Med Sci 55:B418–B424CrossRefPubMed
18.
Chang CC, Ou YC, Raung SL, Chen CJ (2005) Antiviral effect of dehydroepiandrosterone on Japanese encephalitis virus infection. J Gen Virol 86:2513–2523CrossRefPubMed
19.
Acosta EG, Bruttomesso AC, Bisceglia JA, Wachsman MB, Galagovsky LR, Castilla V (2008) Dehydroepiandrosterone, epiandrosterone and synthetic derivatives inhibit Junin virus replication in vitro. Virus Res 135:203–212CrossRefPubMed
20.
Romanutti C, Bruttomesso AC, Castilla V, Bisceglia JA, Galagovsky LR, Wachsman MB (2009) In vitro antiviral activity of dehydroepiandrosterone and its synthetic derivatives against vesicular stomatitis virus. Vet J 182:327–335CrossRefPubMed
21.
Romanutti C, Bruttomesso AC, Castilla V, Galagovsky LR, Wachsman MB (2010) Anti-adenovirus activity of epiandrosterone and dehydroepiandrosterone derivatives. Chemotherapy 56:158–165CrossRefPubMed
22.
Labrie F, Luu-The V, Labrie C, Bélanger A, Simard J, Lin SX, Pelletier G (2003) Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 24:152–182CrossRefPubMed
23.
Reed LJ, Muench HA (1938) A simple method of estimating fifty percent endpoints. Am J Epidemiol 27:493–497
24.
Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63CrossRefPubMed
25.
Atkins C, Evans CW, White EL, Noah JW (2012) Screening methods for influenza antiviral drug discovery. Expert Opin Drug Discov 7:429–438CrossRefPubMed
26.
Shi L, Xiong H, He J, Deng H, Li Q, Zhong Q, Hou W, Cheng L, Xiao H, Yang Z (2007) Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo. Arch Virol 152:1447–1455CrossRefPubMed
27.
Wei Y, Fang W, Wan Z, Wang K, Yang Q, Cai X, Shi L, Yang Z (2014) Antiviral effects against EV71 of pimprinine and its derivatives isolated from Streptomyces sp. Virol J 11:195–209CrossRefPubMedPubMedCentral
28.
Padgett DA, Loria RM, Sheridan JF (2000) Steroid hormone regulation of antiviral immunity. Ann N Y Acad Sci 917:935–943CrossRefPubMed
29.
Loria RM, Padgett DA (1998) Control of the immune response by DHEA and its metbolites. Rinsho Byori 46:505–517PubMed
30.
Diagle J, Carr DJ (1998) Androstenediol antagonizes herpes simplex virus type 1-induced encephalitis through the augmentation of type I IFN production. J Immunol 160:3060–3066
31.
Loria RM, Padgett DA, Huynh PN (1996) Regulation of the immune response by dehydroepiandrosterone and its metabolites. J Endocrinol 150:S209–S220PubMed
Metadata
Title
The inhibitory effect of dehydroepiandrosterone and its derivatives against influenza A virus in vitro and in vivo
Authors
Qingyu Yang
Qing Mao
Manli Liu
Kaimei Wang
Zhaoyuan Wu
Wei Fang
Ziwen Yang
Pengchen Luo
Shaoyong Ke
Liqiao Shi
Publication date
01-11-2016
Publisher
Springer Vienna
Published in
Archives of Virology / Issue 11/2016
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-016-2993-6

Other articles of this Issue 11/2016

Archives of Virology 11/2016 Go to the issue

Original Article

Detection of equine arteritis virus by two chromogenic RNA in situ hybridization assays (conventional and RNAscope®) and assessment of their performance in tissues from aborted equine fetuses

Brief Report

Complete genomic sequence and comparative analysis of four genital and respiratory isolates of bovine herpesvirus subtype 1.2b (BoHV-1.2b), including the prototype virus strain K22

Original Article

“Cytoplasmic domain effects on exposure of co-receptor-binding sites of HIV-1 Env”

Brief Report

Increased pathogenicity of rabies virus due to modification of a non-coding region

Original Article

Exploration of the BF2*15 major histocompatibility complex class I binding motif and identification of cytotoxic T lymphocyte epitopes from the H5N1 influenza virus nucleoprotein in chickens

Brief Report

Molecular detection and genome characterization of porcine circovirus type 2 in rats captured on commercial swine farms
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits